Global Idiopathic Pulmonary Fibrosis Market to Exhibit 23.97% CAGR 2016-2020

Published Date : May 30, 2016

Albany, NY, May 30, 2016: has announced the addition of a new report to its online database of market intelligence. The report discusses the global dynamics of the market for treatments for idiopathic pulmonary fibrosis. The major regional segments of the global idiopathic pulmonary fibrosis and the key players in the market are analyzed in the report to provide a complete review of the market to readers. The report is titled ‘Global Idiopathic Pulmonary Fibrosis 2016-2020’ and is available for sale on the official website of

According to the report, the global idiopathic pulmonary fibrosis market is expected to exhibit a strong 23.97% CAGR from 2016 to 2020.

Idiopathic pulmonary fibrosis is an interstitial lung disease, i.e. it affects the interstitium, or the area around the air sacs in the lungs. This disease is most common among the geriatric demographic, particularly the 50-70 age group. Diagnosis of idiopathic pulmonary fibrosis is made using high-resolution CT and by exclusion of other possible interstitial lung diseases. Concrete, permanent cures for idiopathic pulmonary fibrosis are also lacking at present; the disease is mostly treated by eliminating the symptoms. Nintedanib is one of the two drugs used in the treatment of idiopathic pulmonary fibrosis, along with pirfenidone. However, immunosuppressive drugs and corticosteroids are also used to treat various symptoms of idiopathic pulmonary fibrosis.

Having provided a brief medical overview of the disease, the report analyzes the pipeline of idiopathic pulmonary fibrosis treatment, supplying information about prospective drugs such as lebrikizumab, tralokinumab, simtuzumab, tipelukast, FG-3019, AF-219, BMS-986020, BG00011, PBI-4050, PRM-151, and SAR156597. A brief profile of each under-trial medicine is provided in the report.

For Sample Copy, click here:

According to route of administration of the medicine, the report segments the global idiopathic pulmonary fibrosis market into oral treatments and parenteral treatments. Information regarding the market performance of each type of medicine is given in the report. Likewise, the report segments the idiopathic pulmonary fibrosis market by drug class into anti-fibrotic agents, immunosuppressants, systemic corticosteroids, and tyrosine kinase inhibitors. Geographically, the report segments the global market for idiopathic pulmonary fibrosis treatments into the Americas, APAC, and EMEA (Europe, the Middle East, and Africa).

The report zeroes in on the growing patient population of idiopathic pulmonary fibrosis and rising unmet medical needs as the prime drivers for the global market. On the other hand, the unclear understanding of the etiology of idiopathic pulmonary fibrosis means that diagnosis of the disease is always imprecise. This has also led to the rising usage of off-label treatments, which has emerged as a threat to the global idiopathic pulmonary fibrosis market.

The increasing reliance on mergers and acquisitions is a marked trend observed in the idiopathic pulmonary fibrosis market. Major players such as Baxter International, Boehringer Ingelheim, Promethus Laboratories, and F. Hoffman-La Roche are profiled in the report to provide a comprehensive overview of the competitive dynamics of the global market.

To order report Call Toll Free: 866-997-4948 or send an email on